Arrowhead Pharmaceuticals (ARWR) Competitors $16.74 -0.23 (-1.36%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$16.74 0.00 (0.00%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ARWR vs. BPMC, ROIV, RVMD, VRNA, BBIO, ELAN, GRFS, TLX, TGTX, and NUVLShould you be buying Arrowhead Pharmaceuticals stock or one of its competitors? The main competitors of Arrowhead Pharmaceuticals include Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Verona Pharma (VRNA), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Grifols (GRFS), Telix Pharmaceuticals Limited American Depositary Shares (TLX), TG Therapeutics (TGTX), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. Arrowhead Pharmaceuticals vs. Its Competitors Blueprint Medicines Roivant Sciences Revolution Medicines Verona Pharma BridgeBio Pharma Elanco Animal Health Grifols Telix Pharmaceuticals Limited American Depositary Shares TG Therapeutics Nuvalent Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends. Do institutionals & insiders hold more shares of ARWR or BPMC? 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 4.3% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 4.2% of Blueprint Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor ARWR or BPMC? In the previous week, Blueprint Medicines had 8 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 18 mentions for Blueprint Medicines and 10 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.73 beat Blueprint Medicines' score of 0.56 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Blueprint Medicines 6 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor ARWR or BPMC? Blueprint Medicines received 2 more outperform votes than Arrowhead Pharmaceuticals when rated by MarketBeat users. Likewise, 66.99% of users gave Blueprint Medicines an outperform vote while only 65.40% of users gave Arrowhead Pharmaceuticals an outperform vote. CompanyUnderperformOutperformArrowhead PharmaceuticalsOutperform Votes55265.40% Underperform Votes29234.60% Blueprint MedicinesOutperform Votes55466.99% Underperform Votes27333.01% Which has better earnings and valuation, ARWR or BPMC? Blueprint Medicines has higher revenue and earnings than Arrowhead Pharmaceuticals. Blueprint Medicines is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArrowhead Pharmaceuticals$545.21M4.24-$599.49M-$1.40-11.96Blueprint Medicines$562.12M14.70-$67.09M-$2.47-51.80 Do analysts prefer ARWR or BPMC? Arrowhead Pharmaceuticals currently has a consensus price target of $43.71, suggesting a potential upside of 161.14%. Blueprint Medicines has a consensus price target of $129.35, suggesting a potential upside of 1.10%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arrowhead Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Blueprint Medicines 0 Sell rating(s) 16 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.32 Is ARWR or BPMC more profitable? Arrowhead Pharmaceuticals has a net margin of 0.00% compared to Blueprint Medicines' net margin of -13.19%. Blueprint Medicines' return on equity of -77.49% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Arrowhead PharmaceuticalsN/A -236.60% -64.09% Blueprint Medicines -13.19%-77.49%-20.84% Which has more volatility & risk, ARWR or BPMC? Arrowhead Pharmaceuticals has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. SummaryArrowhead Pharmaceuticals beats Blueprint Medicines on 10 of the 19 factors compared between the two stocks. Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARWR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARWR vs. The Competition Export to ExcelMetricArrowhead PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.31B$6.85B$5.57B$8.62BDividend YieldN/A2.56%5.28%4.18%P/E Ratio-3.248.7827.1720.06Price / Sales4.24255.64410.88157.10Price / CashN/A65.8538.2534.64Price / Book10.876.557.094.70Net Income-$599.49M$143.93M$3.23B$247.88M7 Day Performance1.70%3.97%2.91%2.66%1 Month Performance19.83%11.32%9.09%6.40%1 Year Performance-35.04%4.20%31.75%14.07% Arrowhead Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARWRArrowhead Pharmaceuticals3.6102 of 5 stars$16.74-1.4%$43.71+161.1%-32.1%$2.31B$545.21M-3.24400Analyst RevisionBPMCBlueprint Medicines1.1811 of 5 stars$127.68+26.0%$125.69-1.6%+21.4%$8.24B$562.12M-118.11640High Trading VolumeROIVRoivant Sciences2.3781 of 5 stars$11.12+1.1%$17.50+57.4%+6.7%$7.94B$29.05M-74.16860RVMDRevolution Medicines4.4448 of 5 stars$40.85+3.7%$67.08+64.2%+4.5%$7.63B$742K-11.41250Positive NewsVRNAVerona Pharma2.5029 of 5 stars$84.10+3.6%$82.13-2.3%+573.5%$6.84B$118.54M-43.9130Trending NewsAnalyst ForecastAnalyst RevisionBBIOBridgeBio Pharma4.6128 of 5 stars$35.47+3.5%$57.09+61.0%+42.1%$6.73B$127.42M-12.43400Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionGap UpELANElanco Animal Health1.4106 of 5 stars$13.48+0.3%$15.17+12.6%-22.3%$6.70B$4.43B33.719,800Positive NewsGRFSGrifols3.6544 of 5 stars$8.30-0.2%N/A+28.4%$5.68B$7.21B7.0626,300TLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.79-1.2%$22.00+31.0%N/A$5.67B$783.21M0.00N/APositive NewsTGTXTG Therapeutics2.7751 of 5 stars$35.57+1.3%$40.80+14.7%+137.3%$5.65B$386.39M-355.97290Positive NewsAnalyst RevisionNUVLNuvalent2.1829 of 5 stars$76.70+2.8%$115.50+50.6%-2.7%$5.53BN/A-22.2040Positive News Related Companies and Tools Related Companies Blueprint Medicines Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Verona Pharma Alternatives BridgeBio Pharma Alternatives Elanco Animal Health Alternatives Grifols Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives TG Therapeutics Alternatives Nuvalent Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARWR) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ARWR Stock Free ARWR Stock Alerts